110 related articles for article (PubMed ID: 7438075)
21. Cytotoxicity of ribo-and arabinoside boron nucleosides in tissue culture cells.
Sood A; Spielvogel BF; Powell WJ; Bastow KF; Miller MC; Hall IH
Anticancer Res; 1994; 14(4A):1483-8. PubMed ID: 7979174
[TBL] [Abstract][Full Text] [Related]
22. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin cytotoxicity to P388 lymphocytic leukemia as determined by alkaline elution and established assays.
Russo P; Favoni RE; Zarcone D; Miglietta L; Peluso M; Nicolin A; Bignone F; Parodi S
Anticancer Res; 1986; 6(6):1297-304. PubMed ID: 3813486
[TBL] [Abstract][Full Text] [Related]
24. In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis.
Tanigawa N; Kitaoka A; Yamakawa M; Tanisaka K; Kobayashi H
Anticancer Res; 1996; 16(4A):1925-30. PubMed ID: 8712722
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
26. Effect of high cell density on the growth properties of tumor cells: a role in tumor cytotoxicity of chemotherapeutic drugs.
Singh V; Singh SM
Anticancer Drugs; 2007 Nov; 18(10):1123-32. PubMed ID: 17893512
[TBL] [Abstract][Full Text] [Related]
27. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
30. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
31. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
32. [Drug sensitivity test of cultured human cancer cells--assay for microcolonies inhibition test].
Kitano M; Nagase T
Gan To Kagaku Ryoho; 1982 Apr; 9(4):590-8. PubMed ID: 7184416
[TBL] [Abstract][Full Text] [Related]
33. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL; Zou WY; Song LH; Wei W
Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
[TBL] [Abstract][Full Text] [Related]
34. [Cell test system for the preliminary screening of antitumor preparations].
Kuznetsova NN; Nurizhdaniants SS; Pan ZP; Mukhamedkhanova FS
Vopr Onkol; 1981; 27(12):36-9. PubMed ID: 7324400
[TBL] [Abstract][Full Text] [Related]
35. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
36. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.
Chang BD; Broude EV; Dokmanovic M; Zhu H; Ruth A; Xuan Y; Kandel ES; Lausch E; Christov K; Roninson IB
Cancer Res; 1999 Aug; 59(15):3761-7. PubMed ID: 10446993
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
38. [In vitro tumor sensitivity tests to chemotherapeutic agents by the suppression of dehydrogenase activity].
Ichihashi H; Kondo T
Gan To Kagaku Ryoho; 1982 Apr; 9(4):575-81. PubMed ID: 7184414
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors.
Hornick JL; Khawli LA; Hu P; Sharifi J; Khanna C; Epstein AL
Clin Cancer Res; 1999 Jan; 5(1):51-60. PubMed ID: 9918202
[TBL] [Abstract][Full Text] [Related]
40. Unbalanced cell growth and increased protein synthesis induced by chemotherapeutic agents.
Ross DW
Blood Cells; 1983; 9(1):57-68. PubMed ID: 6683114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
